Alkem Laboratories Ltd. | Large-cap | Healthcare
₹5,428.00
-0.58%
| Alkem Laboratories Stock Comparison:
Alkem Laboratories vs Sun PharmaceuticalAlkem Laboratories vs Divi's LaboratoriesAlkem Laboratories vs TorrentAlkem Laboratories vs CiplaAlkem Laboratories vs Dr. Reddy'sAlkem Laboratories vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 33.7B
Gross Profit 22.0B 65.26%
Operating Income 6.5B 19.32%
Net Income 6.7B 19.81%
EPS (Diluted) ₹55.56

Balance Sheet Metrics

Total Assets 176.9B
Total Liabilities 52.6B
Shareholders Equity 124.3B
Debt to Equity 0.42

Cash Flow Metrics

Revenue & Profitability Trend

Alkem Laboratories Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i128.0B124.4B114.4B105.1B87.3B
Cost of Goods Sold i48.6B50.3B49.8B42.8B35.9B
Gross Profit i79.5B74.1B64.6B62.3B51.4B
Gross Margin % i62.1%59.5%56.4%59.3%58.9%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i16.1B15.8B16.1B13.0B9.1B
Other Operating Expenses i13.5B14.2B11.1B9.0B7.1B
Total Operating Expenses i29.6B30.1B27.2B22.0B16.2B
Operating Income i21.8B19.8B13.3B17.7B16.7B
Operating Margin % i17.1%16.0%11.7%16.8%19.1%
Non-Operating Items
Interest Income i3.6B2.8B1.7B1.2B901.2M
Interest Expense i872.4M957.1M937.5M408.4M488.5M
Other Non-Operating Income-----
Pre-tax Income i25.3B20.2B13.0B18.4B18.4B
Income Tax i3.1B2.1B3.0B1.6B2.2B
Effective Tax Rate % i12.3%10.5%22.8%8.9%12.2%
Net Income i22.2B18.1B10.1B16.8B16.2B
Net Margin % i17.3%14.6%8.8%16.0%18.5%
Key Metrics
EBITDA i29.3B25.3B18.0B21.9B20.8B
EPS (Basic) i₹181.11₹150.19₹82.31₹137.63₹132.57
EPS (Diluted) i₹181.11₹150.19₹82.31₹137.63₹132.57
Basic Shares Outstanding i119565000119565000119565000119565000119565000
Diluted Shares Outstanding i119565000119565000119565000119565000119565000

Income Statement Trend

Alkem Laboratories Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i3.0B4.6B2.7B2.3B1.7B
Short-term Investments i34.7B38.1B8.7B10.8B15.8B
Accounts Receivable i24.7B22.5B21.3B18.8B16.1B
Inventory i29.2B26.6B26.1B30.1B23.1B
Other Current Assets185.4M214.2M221.1M226.7M163.8M
Total Current Assets i109.5B104.1B87.3B84.4B69.3B
Non-Current Assets
Property, Plant & Equipment i23.9B2.5B1.4B1.4B22.3B
Goodwill i9.6B8.9B9.1B8.8B9.5B
Intangible Assets i1.1B575.8M793.8M721.9M1.6B
Long-term Investments-----
Other Non-Current Assets-300.0K839.5M-100.0K200.0K200.0K
Total Non-Current Assets i67.5B51.6B50.3B56.3B45.9B
Total Assets i176.9B155.7B137.6B140.7B115.2B
Liabilities
Current Liabilities
Accounts Payable i18.4B17.5B11.7B11.7B10.7B
Short-term Debt i8.0B11.9B13.3B25.9B16.9B
Current Portion of Long-term Debt-----
Other Current Liabilities3.1B2.3B100.0K1.5B1.2B
Total Current Liabilities i39.6B39.9B37.1B48.1B36.0B
Non-Current Liabilities
Long-term Debt i5.8B2.3B703.3M758.5M976.4M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities219.5M258.4M-200.0K79.2M88.3M
Total Non-Current Liabilities i12.9B8.7B6.1B4.2B3.6B
Total Liabilities i52.6B48.6B43.2B52.2B39.6B
Equity
Common Stock i239.1M239.1M239.1M239.1M239.1M
Retained Earnings i99.7B83.1B70.5B65.9B53.7B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i124.3B107.1B94.4B88.5B75.6B
Key Metrics
Total Debt i13.8B14.2B14.0B26.7B17.9B
Working Capital i69.8B64.2B50.2B36.3B33.2B

Balance Sheet Composition

Alkem Laboratories Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i25.3B20.2B13.0B18.4B18.4B
Depreciation & Amortization i-----
Stock-Based Compensation i166.1M189.4M001.1M
Working Capital Changes i-4.5B-4.3B2.6B-9.4B-6.2B
Operating Cash Flow i18.4B14.5B15.0B8.2B11.9B
Investing Activities
Capital Expenditures i-6.3B-1.9B-2.3B-3.3B-1.8B
Acquisitions i-330.0M----
Investment Purchases i-56.9B-36.8B-2.2B-12.1B-9.3B
Investment Sales i47.2B26.2B4.1B--
Investing Cash Flow i-16.5B-12.5B-342.6M-15.3B-11.1B
Financing Activities
Share Repurchases i-----
Dividends Paid i-5.0B-5.4B-5.3B-4.2B-3.3B
Debt Issuance i2.9B----
Debt Repayment i-4.8B---192.9M-387.4M
Financing Cash Flow i-11.8B-10.6B-16.4B4.4B-2.0B
Free Cash Flow i12.4B16.9B14.5B7.7B10.7B
Net Change in Cash i-9.9B-8.6B-1.7B-2.7B-1.1B

Cash Flow Trend

Alkem Laboratories Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 28.55
Forward P/E 25.52
Price to Book 5.45
Price to Sales 4.91
PEG Ratio 1.31

Profitability Ratios

Profit Margin 17.17%
Operating Margin 19.32%
Return on Equity 17.42%
Return on Assets 12.24%

Financial Health

Current Ratio 2.76
Debt to Equity 11.11
Beta 0.34

Per Share Data

EPS (TTM) ₹191.24
Book Value per Share ₹1,002.37
Revenue per Share ₹1,112.68

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
alkem661.8B28.555.4517.42%17.17%11.11
Sun Pharmaceutical 3.9T36.745.3015.08%19.29%3.26
Divi's Laboratories 1.6T65.3610.0914.64%23.89%0.03
Torrent 1.2T60.3515.9025.18%16.92%42.81
Cipla 1.2T22.853.9216.85%19.62%1.40
Dr. Reddy's 1.1T18.222.9117.71%16.99%13.75

Financial data is updated regularly. All figures are in the company's reporting currency.